CETIGAL Tablet contains Cetirizine Hydrochloride, a second-generation non-sedating antihistamine widely used for the treatment of allergic rhinitis, urticaria, hay fever, and other allergic conditions. It provides fast, long-lasting relief from symptoms such as sneezing, runny nose, itchy eyes, and hives. CETIGAL is formulated for once-daily dosing, offering 24-hour efficacy with minimal drowsiness. Manufactured by BluepillExpress under stringent international quality standards, CETIGAL is an ideal choice for both domestic and global pharmaceutical markets.

This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.

CETIGAL Tablet is a trusted antihistamine formulation containing Cetirizine Hydrochloride, designed for effective, long-lasting relief from a wide spectrum of seasonal and perennial allergic conditions. As a second-generation antihistamine, Cetirizine offers the advantage of potent H1 receptor antagonism with minimal sedative effects, making it a first-line option for patients seeking uninterrupted daily functionality while managing allergy symptoms.

Cetirizine, the active ingredient in CETIGAL, acts by selectively blocking histamine H1 receptors, thereby preventing the cascade of allergic responses triggered by histamine release from mast cells. This action results in the reduction of common allergic symptoms including nasal congestion, rhinorrhea (runny nose), sneezing, watery eyes, and itching of the throat or skin. CETIGAL Tablet begins acting within 30 to 60 minutes of ingestion and provides therapeutic relief for up to 24 hours, enabling once-daily administration that boosts patient compliance.

CETIGAL is particularly effective in treating seasonal allergic rhinitis (hay fever), perennial allergic rhinitis, chronic idiopathic urticaria, and other forms of dermatological hypersensitivity, such as eczema and contact dermatitis. It is also useful in treating allergic conjunctivitis and mild allergic asthma as an adjunct therapy. Due to its minimal central nervous system penetration, Cetirizine is significantly less sedating than first-generation antihistamines such as diphenhydramine or hydroxyzine, offering an improved safety profile for daytime use.

Pharmacologically, Cetirizine is rapidly absorbed after oral administration, reaching peak plasma concentration within one hour. The drug has a plasma half-life of approximately 8 to 10 hours and is primarily eliminated via the kidneys. It undergoes limited hepatic metabolism, which reduces the risk of drug interactions. This makes CETIGAL a suitable antihistamine for elderly patients or those on multiple medications, provided renal function is monitored.

Clinically, CETIGAL is well tolerated by a wide range of patients including adolescents, adults, and the elderly. It is not recommended for children below 6 years unless specifically prescribed in pediatric formulations. The incidence of side effects is low, with occasional reports of mild drowsiness, dry mouth, headache, or gastrointestinal discomfort, all of which are generally self-limiting. The low sedative and anticholinergic profile of Cetirizine further improves its suitability for chronic use in allergy-prone individuals.

Manufactured by BluepillExpress, CETIGAL Tablet undergoes rigorous quality control processes compliant with WHO-GMP, ISO 9001:2015, and US FDA-export compliant standards. Each tablet is produced in state-of-the-art facilities with complete adherence to Good Manufacturing Practices (GMP), ensuring precise dosage, consistent efficacy, and safety. Raw materials are sourced only from certified suppliers and tested for identity, potency, and purity before use in production.

CETIGAL is typically offered in 10 mg strength, which is the standard adult dose recommended for once-daily use. Custom strengths (e.g., 5 mg) and pediatric formats (e.g., syrups or dispersible tablets) can also be manufactured on demand for global partners. Packaging options include Alu-Alu or blister packs, with multilingual labeling and design support provided for regulatory approvals across different geographies including Africa, CIS countries, the Middle East, Southeast Asia, and Latin America.